Technical Analysis for BDTX - Black Diamond Therapeutics, Inc.

Grade Last Price % Change Price Change
F 26.14 0.11% 0.03
BDTX closed up 0.11 percent on Friday, January 22, 2021, on 1.44 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical BDTX trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Stochastic Buy Signal Bullish 0.11%
Lower Bollinger Band Walk Weakness 0.11%
Wide Bands Range Expansion 0.11%
Lower Bollinger Band Touch Weakness 0.11%
Oversold Stochastic Weakness 0.11%
Older End-of-Day Signals for BDTX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 1% about 3 hours ago
60 Minute Opening Range Breakout about 7 hours ago
Down 1% about 7 hours ago
Lower Bollinger Band Support about 7 hours ago
Down 5% 1 day ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Black Diamond Therapeutics, Inc., a biotechnology company, discover and develops small molecule, tumor-agnostic therapies for cancer treatment. Its lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR) and tyrosine-protein kinase. The company is also developing allosteric-EGFR mutation inhibitors; and various early stage pipeline programs of allosteric mutations in kinases related to cancer and/or rare genetic diseases. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Enzymes Cancer Treatment Diamond Genetic Disease Epidermal Growth Factor Receptor Genetic Diseases Therapies For Cancer Tyrosine Kinase Receptors Oncogenes Rare Genetic Disease Protein Kinase Rare Genetic Diseases Black Diamond Kinase

Is BDTX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 46.25
52 Week Low 17.63
Average Volume 392,578
200-Day Moving Average 33.36
50-Day Moving Average 32.50
20-Day Moving Average 31.03
10-Day Moving Average 29.04
Average True Range 2.02
ADX 24.99
+DI 10.38
-DI 31.38
Chandelier Exit (Long, 3 ATRs ) 31.69
Chandelier Exit (Short, 3 ATRs ) 31.67
Upper Bollinger Band 36.91
Lower Bollinger Band 25.15
Percent B (%b) 0.08
BandWidth 37.89
MACD Line -1.75
MACD Signal Line -1.08
MACD Histogram -0.6773
Fundamentals Value
Market Cap 940.93 Million
Num Shares 36 Million
EPS -1.08
Price-to-Earnings (P/E) Ratio -24.20
Price-to-Sales 0.00
Price-to-Book 3.54
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 27.31
Resistance 3 (R3) 27.31 26.92 27.12
Resistance 2 (R2) 26.92 26.62 26.92 27.05
Resistance 1 (R1) 26.53 26.44 26.73 26.53 26.98
Pivot Point 26.14 26.14 26.24 26.14 26.14
Support 1 (S1) 25.75 25.84 25.95 25.75 25.30
Support 2 (S2) 25.36 25.66 25.36 25.23
Support 3 (S3) 24.97 25.36 25.17
Support 4 (S4) 24.97